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Versican v0 and v1 direct the growth of peripheral axons in the
developing chick hindlimb
Abstract
Peanut agglutinin-binding disaccharides and chondroitin sulfate mark transient mesenchymal barriers to
advancing motor and sensory axons innervating the hindlimbs during chick development. Here we show
that the vast majority of these carbohydrates are at the critical stage and location attached to the versican
splice variants V0 and V1. We reveal that the isolated isoforms of this extracellular matrix proteoglycan
suppress axon extension at low concentrations and induce growth cone collapse and rapid retraction at
higher levels. Moreover, we demonstrate that versican V0 and/or V1, recombinantly expressed in
collagen-I gels or ectopically deposited in the hindlimbs of chicken embryos in ovo, cause untimely
defasciculation and axon stalling. Consequently, severe disturbances of nerve patterning are observed in
the versican-treated embryos. Our experiments emphasize the inhibitory capacity of versicans V0 and
V1 in axonal growth and evidence for their function as basic guidance cues during development of the
peripheral nervous system.
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Peanut agglutinin-binding disaccharides and chondroitin sulfate mark transient mesenchymal barriers to advancing motor and
sensory axons innervating the hindlimbs during chick development. Here we show that the vast majority of these carbohydrates
are at the critical stage and location attached to the versican splice variants V0 and V1. We reveal that the isolated isoforms of this
extracellular matrix proteoglycan suppress axon extension at low concentrations and induce growth cone collapse and rapid
retraction at higher levels. Moreover, we demonstrate that versican V0 and/or V1, recombinantly expressed in collagen-I gels or
ectopically deposited in the hindlimbs of chicken embryos in ovo, cause untimely defasciculation and axon stalling. Consequently,
severe disturbances of nerve patterning are observed in the versican-treated embryos. Our experiments emphasize the inhibitory
capacity of versicans V0 and V1 in axonal growth and evidence for their function as basic guidance cues during development of the
peripheral nervous system.
Introduction
The establishment and stabilization of the neuronal circuitry
during development and postnatal maturation greatly relies on a
timely and spatially coordinated program regulating the delicate
balance between axon growth promotion and inhibition. In the
developing peripheral nervous system (PNS), the delineation of
barrier tissues blocking axonal growth and forcing advancing
axons into their designated trajectories constitutes one of the initial
steps of the highly complex guidance process (Tosney, 1991). This
earlyphaseofmotorandsensory innervation is at leastpartlyaccom-
panied by the selective deposition and turnover of inhibitory extra-
cellular matrices (ECMs). Once pioneering axons have begun to
invade permissive mesenchymal tissues and successive nerve fibers
have followed by fasciculation, a refined system of diffusible and
stationary attractants and repellents in combination with specific
receptor sets on the advancing growth cones controls numerous
branch point decisions and directs segregating axons toward their
individual targets (Landmesser, 2001; Hanson et al., 2008).
The nonpermissivemesenchymal tissues, consistently border-
ing the pathways of migratory neural crest cells and growing
axons during early PNS development, are particularly rich in
chondroitin sulfate proteoglycans (CSPGs) and peanut aggluti-
nin (PNA)-binding glycoproteins (Tosney and Landmesser,
1985; Oakley and Tosney, 1991). In the trunk of the chicken
embryo, these temporary boundaries include the posterior scle-
rotome, the perinotochordal region, and the early subectodermal
zone. CSPGs are also abundantly expressed in the developing
hindlimbs. The early limb bud tissue blocks innervation initially
in its entirety and delays axonal extension from the plexus region
by24 h (Wang and Scott, 2000). After this period, most of the
nonpermissive areas have regressed and are ultimately confined
to the condensing mesenchyme of the pelvic girdle and other
pre-chondrogenic areas.
Prominently represented in all these transient barriers of the
trunk and limb anlage are the two largest splice variants of the
extracellular matrix CSPG versican, V0 and V1 (Landolt et al.,
1995). Intriguingly, other members of the lectican/hyalectan
family of CSPGs, including the smaller versican isoform V2, are
similarly expressed in nonpermissive tissues of the developing or
mature CNS and exert potent axon growth inhibitory activity
(Bandtlow and Zimmermann, 2000; Schmalfeldt et al., 2000;
Zimmermann and Dours-Zimmermann, 2008). Despite this ap-
parent analogy to axon growth-suppressing roles of CSPGs in the
CNS, a functional link between the selective expression and turn-
over of versican V0 and V1 and the nonpermissive character of
matrices flanking axon trajectories during PNS formation has not
been established so far.
Therefore, we have isolated intact versican V0 and V1, ex-
plored their inhibitory potential in a series of functional anal-
yses with dorsal root explants in vitro, and analyzed their
impact on axonal patterning in the developing limb by ectopi-
cal deposition in vivo.
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Materials andMethods
Antibodies and versican preparations. Polyclonal antibodies against spe-
cific domains of bovine, human, mouse, and chick versican were affinity
purified from rabbit antisera prepared previously by our laboratory
(Zimmermann et al., 1994; Landolt et al., 1995; Schmalfeldt et al., 1998,
2000). The anti-proteoglycan Di-6S monoclonal antibody 3-B-3 was
obtained from Seikagaku. The monoclonal antibody RMO-270 against
neurofilament-160 kDa (anti-NF-M) (Invitrogen) and goat polyclonal
antibodies against axonin-1 (Ruegg et al., 1989) were used for axon and
growth cone labeling. Lectin staining of tissue sections was done with
PNA and goat anti-PNA antibodies (both fromVector Laboratories). Fluo-
rescent secondary antibodies included (1) Alexa Fluor-488 goat anti-rabbit
IgG and Alexa Fluor-594 goat anti-mouse IgG for cell culture stainings, (2)
Alexa Fluor-488 donkey anti-rabbit IgG, Alexa Fluor-555 donkey anti-
mouse IgG, and Alexa Fluor-647 donkey anti-goat IgG (Invitrogen) for tri-
ple stainings of tissues sections, and (3) cyanine 3 (Cy3)-labeled goat
anti-mouse secondary antibodies (Jackson ImmunoResearch) for whole-
mountNFstainings, respectively. Secondaryantibodies for immunoblotting
experiments were also from Jackson ImmunoResearch.
Versican isoforms used in the in vitro and in vivo studies were purified
from conditioned medium of the human glioma cell line U251MG and
from calf aorta as described previously (Dutt et al., 2006). Versican core
glycoproteins used in some experiments were obtained by removal of the
glycosaminoglycan chains through digestion with chondroitinase ABC
(Seikagaku).
Blotting techniques. Extracts from Hamburger and Hamilton stage 21
to 22 (HH21/22, (Hamburger and Hamilton, 1951) chick trunks and
hindlimbs, conditioned media from embryonic day 13 (E13) chick em-
bryonic fibroblast, and U251MG cell cultures as well as control extracts
of postnatal day 30 (P30) brains of wild-type and versican V0/V2 knock-
out mice (Dours-Zimmermann et al., 2009) were analyzed by lectin and
immunoblotting. Samples were run on 4–15% Phastgels (GE Health-
care) and processed according to Zimmermann et al. (1994). For the
detection of PNA-binding proteins, proteoglycans, and versicans, we
used aDIG-GlycanDifferentiation kit (Roche Applied Science), amono-
clonal antibody against chondroitin sulfate stubs or our polyclonal anti-
bodies against versican, respectively.
Neurite outgrowth assays. Stripe-choice analyses of neurites extending
from intact or dissociated explants of dorsal root ganglia (DRG) of E10–
E11 chick embryos were essentially done as described (Vielmetter et al.,
1990; Schmalfeldt et al., 2000). In brief, surface-treated glass coverslips
were coated in alternating stripes covered with either test substrates ad-
mixed to 100 g/ml laminin-1 or with 20 g/ml laminin-1 alone (Invit-
rogen). The test substrate solutions contained, apart from laminin-1,
intact or chondroitinase ABC-digested versican V1 or a versican V0/V1
mixture at concentrations of 10–100g/ml. TheDRGs were placed onto
the stripe pattern and cultured in DMEM/F-12 1:1 medium containing
10% FCS, 2% chicken serum, 100U/ml penicillin, 100g/ml streptomy-
cin, 100 ng/ml nerve growth factor 7S (all from Invitrogen), 10 mM
cytosine arabinoside, and 0.5%methylcellulose (both fromSigma). After
2–3 d of incubation in a 5%CO2 atmosphere at 37°C, the explant cultures
were fixed in 4%paraformaldehyde/0.33% sucrose in PBS for 10min and
subsequently analyzed by immunofluorescence. For some experiments,
laminin-1 was replaced by fibronectin (Roche Diagnostics) as neurite
growth-supporting substrate.
To test growth cone behavior in time-lapse videomicroscopy, half of a
pretreated glass coverslip was first manually covered with a mixture of
100g/ml versicanV0/V1 and 100g/ml laminin-1, followed by coating
of the remaining surface with 20 g/ml laminin-1 alone. The border of
the test substrate area was delineated on the back of the slide with a
marker pen. DRGs from E10 chick embryos were placed near the
versican-coated area, and neurites were allowed to grow under a Leica
DM IRBE wide-field microscope equipped with a culture chamber con-
trolling temperature and CO2 conditions (37°C and 5%). Images of
growth cone movement toward the versican-coated region were cap-
tured with a Hamamatsu Orca ER camera using a phase-contrast PH1 N
Plan L 20/0.40 objective. Frames were captured every 30 s and analyzed
with the Openlab 3.1.5 software.
Cocultures of DRGs and transfected COS cells. COS cells were tran-
siently transfected with either an empty pSecTagA vector (Invitrogen)
(mock transfection) or with a pSecTagA construct, in which the recon-
stituted full-length cDNA of themature human versican V1 core protein
including its native stop codon had been inserted into the vector after the
Ig secretory leader sequence (Zimmermann and Ruoslahti, 1989). COS
cell aggregates were prepared in hanging drops as described (Kennedy et
al., 1994). For cocultures, COS cell aggregates were placed in solidifying
collagen-I gels in close vicinity to DRGs fromE10 chick embryos (Lumsden
andDavies, 1983) and subsequently incubated at 37°C inDMEM/F-12 (1:1)
medium containing 10% FCS, 2% chicken serum, 2 mM L-glutamine, 100
U/ml penicillin, 100 g/ml streptomycin, and 100 ng/ml 7S NGF (all from
Invitrogen). After 3.5–4 d, the three-dimensional cultures were fixed in 4%
paraformaldehyde/0.33%sucrose inPBSandprocessed for immunofluores-
cence staining.
In ovo injections of versican.Hisex chick embryos were staged accord-
ing to Hamburger and Hamilton (1951). In ovo injections were per-
formed as described previously (Stoeckli and Landmesser, 1995). After
local removal of the extra-embryonic membrane, injections into the
hindlimb were done with a pointed glass capillary (tip diameter of 5
m) attached to Teflon tubing. The test substrates in PBS were mixed
with trypan blue (final concentration 0.04% v/v; Invitrogen) to control
localization and volume of the injection. Injections were done into the
right hindlimb at three different positions near the plexus region, two
paraxial and one distal (Fig. 1). Less than 1 l of the test solution with
versican concentrations of 180 or 400 g/ml (V1 and V0/V1 prepara-
tions, respectively) was deposited at each time point. First injections
were done at HH18–HH19 and subsequently repeated in regular in-
Figure 1. Chick embryo at HH21/HH22 before (A) and after (B) in ovo injection of the trypan
blue-containing versican solution.
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tervals for three to four times until the em-
bryo reached HH22–HH23. After every
manipulation, the eggs were resealed with
paraffin and a glass coverslip and incubated
at 39°C. At the end of the in ovo experiment
(HH25/HH26), embryos were collected,
eviscerated, freed of residual blood, and
fixed in 4% paraformaldehyde before whole-
mount staining.
Immunohistological and lectin staining proce-
dures. For the combined immunofluorescence
and PNA stainings of chick embryo sections,
we adapted previously described protocols
(Oakley and Tosney, 1991; Schmalfeldt et al.,
2000). In brief, the isolated embryos were fixed
overnight in 4% paraformaldehyde containing
0.5% cetylpiridinium chloride, dehydrated,
and paraffin embedded. Glass slides carrying
4-m-thick tissue sections were dewaxed, and
antigens were retrieved in 10 mM trisodium ci-
trate, pH 6.0, under controlled conditions
(antigen-retrieval device FSG 120-T/T; Mile-
stone). Sectionswere then blockedwithCarbo-
Free blocking solution for 90 min and
incubated with 10 g/ml PNA in 10 mM
HEPES, 150mMNaCl, and 1mMCaCl2, pH 7.5
for 3 h (all PNA-staining reagents from Vector
Laboratories). The binding of the primary an-
tibodies in PBS containing 0.5% BSA, 0.2%
gelatin, and 0.02% NaN3 was allowed to pro-
ceed overnight at 4°C. The antibody dilutions
were 1:400 for anti-PNA, 1:500 for the anti-
bodies against versican GAG-, and 1:2000
against neurofilament-M. The subsequent
incubation with Alexa Fluor-labeled second-
ary antibodies (all 1:200 dilution; Invitro-
gen) for 1–2 h was in some experiments
followed by counterstaining with Hoechst
H33258 bis-benzimide (Invitrogen). Pri-
mary and secondary antibody binding of
fixed dorsal root ganglia explant cultures was
done analogously, but antibodies were di-
rectly applied after initial blocking with 0.5%
BSA, 0.2% gelatin, and 0.02% NaN3 in PBS
(Schmalfeldt et al., 2000). Stained cell cultures
and tissue sections were finally mounted in flu-
orescence mounting medium (Dako).
For whole-mount staining of nerve fibers, fixed embryos were washed
in PBS and permeabilized in 1% Triton X-100/PBS for 1 h at room
temperature. After rinsing in PBS, they were incubated for 1 h in 20 mM
lysine, 0.1 M sodium phosphate, pH 7.4, subsequently washed five times
in PBS for 10min, and subjected to blocking in 10% fetal calf serum/PBS
for at least 2 h at room temperature. Incubation with the monoclonal
antibody against neurofilament-M (dilution 1:1500) was performed for
48 h at 4°C. After five short and one last prolonged incubation in PBS
(12 h), embryoswere again submerged in blocking buffer for 2 h before
binding of Cy3-labeled secondary antibodies (diluted 1:500) overnight at
4°C. Unbound antibodies were removed by six extensive PBS washing
steps at room temperature (at least two times for2 h plus last incuba-
tion overnight). Finally, the embryos were dehydrated in an increasing
methanol series (25, 50, 75, and 100%; each step for30 min) and then
transferred into 2:1 benzyl benzoate/benzyl alcohol.
Fluorescence photomicrographs were taken with an Olympus BX61
(cells/sections) or a SZX12 microscope (whole mounts) equipped with a
F-view camera. Image capture and analysis was performed using the Analy-
SISPro software (Soft Imaging System). Monochromatic fluorescence im-
ages were imported into separate color channels in Photoshop and
superimposed.
Results
Independent histological studies by Oakley and Tosney and by
our group have previously revealed strict complementarities be-
tween axonal growth patterns and the distribution of PNA-
binding carbohydrates, chondroitin-6-sulfate (Oakley and
Tosney, 1991), and the versican isoforms V0/V1 (Landolt et al.,
1995) during motor and sensory innervation of the trunk and
limbs in the chicken. Although the originallymonochrome stain-
ings were suggestive of a close association of these mesenchymal
components with axon growth-impeding boundary tissues, par-
ticularly the interconnection between the PNA-bindingmolecule
and the chondroitin sulfate-carrying versicans remained rather
obscure. For this reason, we have first attempted to clarify this
relationship before embarking on extensive functional studies in
vitro and in vivo.
Versicans are the major PNA-binding proteins in the
developing trunk and limb buds
Our triple fluorescence stainings simultaneously detecting PNA-
binding carbohydrates, versicans V0/V1, and neurofilaments
Figure 2. Temporospatial relationship of PNA-binding sites, versican V0/V1, and axonal growth in the developing hindlimb.
Triple lectin/immunofluorescence stainings of cross-sections of HH22 and HH26 chicken embryos at hindlimb level reveal the
primarily overlappingpatterns of PNA ligands (dark blue inmerged image) and versicanV0/V1 (green). AtHH22, both components
are ubiquitously distributed in the perinotochordal region and the early limb bud but absent from the pathways of motor and
sensory axons (red), which have reached the plexus region and are momentarily hindered from entering the limb. At HH26,
versican and PNA-binding sites have disappeared from the prospective axon routes but persist in the pelvic girdle precursor, in the
forming dermis, and the condensing mesenchyme adumbrating the future leg bones. Scale bar, 200m.
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now clearly demonstrate a broad overlap of versican-specific im-
munoreactivity and PNA-binding sites in mesenchymal barriers
and confirm the virtual absence of both components from the
axonal pathways in the chick embryonic trunk and the develop-
ing hindlimbs (Fig. 2). For instance, at stage HH22, when the
growingmotor and sensory axons have joined but are still locked
within the plexus region, the entire hindlimb is intensely labeledby
both PNA–lectin and versican-specific antibodies. At this time,
considerable versican V0/V1 depositions are also found in the
perinotochordal region, particularly in immediate vicinity to the
notochord, whereas the staining of the PNA–lectin in this area
appears more uniform and widespread. Unlike versican, PNA
binding is additionally detected within the neural tube and in the
ectodermal layer. Later in hindlimb development (HH26), versi-
can and the PNA-binding carbohydrate become confined to the
pelvic girdle, to the subectodermal region, and to the condens-
ing mesenchyme of the pre-chondrogenic zones. The trajecto-
ries of the advancing nerve fibers and the more distal areas of
future axonal invasion are essentially free of PNA and versican
staining. Although PNA-binding carbohydrates are still present in
the perinotochordal region, the versican V0/V1 immunoreactivity
has greatly diminished in this area. At this stage, the PNA-binding
activity also persists in the neural tube (except for the motor col-
umns) and in the ectoderm.
The rather striking colocalization of PNA-binding molecules
and the versican immunoreactivity within the early mesenchyme
supports the hypothesis that the highly glycosylated versicans V0
and V1 might carry not only chondroitin sulfate but also galac-
tosyl (-1,3) N-acetylgalactosamine, the oligosaccharide recog-
nized by PNA. We have therefore extracted early embryonic
trunks and hindlimb buds (HH21/HH22) with a detergent-
containing high-salt buffer to solubilize extracellular matrix and
cell surface molecules, and we have subsequently performed
PNA–lectin blotting and versican V0/V1-
specific immunoblotting (Fig. 3). Com-
parisons of these analyses demonstrate
that versicans, and in particular the V0
isoform, in fact account for most of the
PNA-binding activity in the early chick
trunk and limb extracts. Moreover, nearly
exclusive staining of versican V0 and V1 is
observed on PNA–lectin blots of condi-
tioned culture media from chick primary
embryonic fibroblasts and from the hu-
man glioma cell line U251. Akin to the
larger V0 and V1 isoforms, versican V2
seems to represent the major PNA-
binding component of the mature CNS,
because brain extracts of knock-out mice
selectively lacking this isoform (Dours-
Zimmermann et al., 2009) have lost virtu-
ally all of the PNA reactivity alongwith the
V2 variant.
Versican V0 and V1 are potent neurite
outgrowth inhibitors in vitro
To examine the inhibitory capacity of the
large versican isoforms, we have per-
formed various functional assays with
chick DRG explants in vitro. In stripe-
choice experiments, we have first exposed
the outgrowing sensory axons to alternat-
ing lanes coated either with the neurite
growth-promoting ECM–glycoprotein laminin-1 alone or with
mixtures of laminin-1 and intact versican V1 or versican V0/V1
preparations isolated as described (Dutt et al., 2006). Despite the
high laminin level present on both surfaces, robust extension of
DRG neurites is confined to the substrate stripes that lack versi-
can (Fig. 4). Versican overrides the axon growth-promoting ac-
tivity not only of laminin-1. Similar inhibitions can also be
observed, when fibronectin (Fig. 5) or collagen-I (data not
shown) are used as growth-promoting substrates in this assay.
Because laminin-1 is the most effective substrate and therefore
widely used for in vitro studies, we have performed the subse-
quent stripe-choice experiments with this standard neurite out-
growth promoter. Even under these optimal conditions, a partial
reversion of the laminin-induced growth can already be ob-
served, when as little as 10g/ml versicanV1 or V0/V1mixture is
included in the 100 g/ml laminin coating solution (Fig. 6). At
versican concentrations of 25–50 g/ml, the avoidance by the
neurites is nearly complete. This inhibitory activity of versicanV0
and V1 is reduced, but not abolished, when the chondroitin sul-
fate side chains are removed by chondroitinase ABC digestion.
Compared with the intact proteoglycan preparations, the coating
concentrations of the core glycoproteins have to be approxi-
mately doubled to achieve similar axonal avoidance reactions.
Although lower versican V0 and V1 concentrations may pro-
voke stalling and/or turning of the axonal tip, higher concentra-
tions induce growth cone collapse and rapid retraction. We have
recorded this latter behavior by time-lapse video microscopy
(Fig. 7), in which we confronted DRG neurites growing on a 100
g/ml coat of laminin-1 to a surface treated with laminin-1 and
versican V0/V1 at dilutions of 100 g/ml each. In these experi-
ments, the neurites advance on the laminin-1 substrate at a speed
of 120–150 m/h and display extended growth cone morpholo-
gies. Once they have contacted the versican-containing zone,
Figure 3. Identification of versicans as major PNA-binding proteins. Extracts of hindlimbs (A) and trunks (B) from HH21 chick
embryos, supernatants of chick embryonic fibroblasts (C), and of human U251 glioma cell cultures (D) and brain extracts of P30
wild-type (WT) and versican V0/V2 knock-outmice (E; KO) were analyzed by lectin and immunoblotting with PNA and antibodies
against versicans and against chondroitin-6-sulfate stubs (Di-6S), respectively. Some of the samples were digested with chon-
droitinase ABC () to remove the GAG side chains. The domain-specific antibodies against versican are reactive with the chick
variants V0/V1 (chGAG), the chick andmouse isoformsV0/V2 (chGAG,mGAG), or all proteoglycan variants of humanversican
(hGAG/). The bands of the different core glycoproteins of versicans (V0, V1, and V2) and of aggrecan (Ac) are indicated by
arrowheads.
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however, the growth cones immediately collapse and the axons
retract with a three to four times higher velocity. This retrograde
movement slows down after a while and then stops, the growth
cones restore, and axonal growth is reinitiated. Similarly, growth
cones advancing on laminin-1 alone in the stripe-choice format
constantly explore the neighboring lanes containing high versi-
can concentrations but invariably collapse when they reach the
end of the versican-free lane (Fig. 7).
In the final experiments of our in vitro series, we have analyzed
the influence of versican deposition on axonal growth in three-
dimensional collagen-I matrices. Also in this more in vivo-like
setting, we obtained clear evidence for a dominant inhibitory
effect of versican overriding the axon growth promotion, this
time exerted by the collagen substrate. In the collagen gel assay
(Fig. 8), axons frequently extend from the DRG explants in the
form of robust nerve bundles. However, as soon as they approach
the neighborhood of COS cells, which recombinantly express
full-length versican V1, they begin to defasciculate and then stop
before reaching the aggregates. In contrast, mock-transfected
control aggregates devoid of versican expression do not affect
neurite outgrowth.
Ectopical deposition of versican V0 and V1 disturbs axon
patterning in developing hindlimbs in vivo
Untimely defasciculation and aberrant axon routings are also
observed in vivo, when versican V1 or V0/V1 are ectopically de-
posited in the nerve pathways of the developing hindlimb. Re-
peated in ovo injections of versicans between HH18 and HH23
resulted in aberrant branching of developing peripheral nerves at
HH25/HH26. Whole mounts stained with anti-neurofilament
antibodies were scored blind to the experimental condition for
axonal branching in the developing hindlimbs (Fig. 9). As main
indicators, we scored abnormal exit points (criterion 1) and ir-
regular branching of secondary nerve fibers (criterion 2) emerg-
ing from the dorsal trunk of the sciatic plexus. This way, we
revealed moderate to severe disturbances (only one or both cri-
teria fulfilled, respectively) of axonal growth behavior in the vast
majority of the embryos, in which the natural formation of
versican-free pathways was counteracted by our exogenous ver-
sican supply. Conversely, irregularities of sciatic nerve formation
were only very rarely seen in control-injected embryos by the
three independent observers of this blinded study.
In summary, all our analyses emphasize the inhibitory po-
tential of versican V0 and V1 in axon growth regulation by
inducing defasciculation, deflection, and repulsion of neuro-
nal processes depending on the concentration within the ex-
tracellular matrix.
Figure 4. Versican overrides the neurite growth-promoting activity of laminin-1 in a
stripe-choice assay. A, Overlay of false color images of a triple immunofluorescence stain-
ing of laminin-1 (LN; blue), versican (VC; green), and neurofilaments (white). Despite the
rather uniform distribution of the growth-promoting substrate laminin-1, neurites from
E10 chick dorsal root ganglions avoid stripes coated with laminin-1 plus versican V0/V1
(100 g/ml coating concentration) and advance on lanes coated with laminin-1 alone.
The laminin- and the versican-specific stainings are also depicted separately in B and C,
respectively. Scale bar, 50m.
Figure 5. Versican-mediated inhibition of neurite outgrowth on fibronectin. Although neu-
rites fromanE10 chick dorsal root ganglion extend freely onalternating substrate stripes coated
with 20 and 100 g/ml fibronectin (A), they are rapidly forced into versican-free lanes on
alternating stripes of fibronectin alone (coated with 20g/ml) and fibronectin plus versican
V0/V1 (100g/ml each) substrates (B). Phase-contrast and versican-specific immunofluores-
cence images. Scale bar, 100m.
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Discussion
The guidance process that directs sensory and motor axons with
utmost precision toward their individual targets in the hindlimb
operates on multiple levels. At the lowest level, general cues di-
vide the early mesenchyme into permissive and non-permissive
areas for axon growth (Tosney, 1991; Landmesser, 2001).
Through short-range contact, they roughly indicate the prospec-
tive nerve routes and transiently block inappropriate and/or pre-
mature innervation of differentiating tissues. Although the axons
following these basic pathways intermingle initially in the spinal
nerves, they subsequently segregate within the plexus region into
separate pools, which already bear the capacity to later respond
differentially to region-specific cues within the developing limbs.
Rhythmic electrical bursts originating from the early spinal cord
appear to sustain this axonal pooling and, hence, further influ-
ence subsequent pathfinding decisions (Hanson et al., 2008).
Controlled by this second-level andmore sophisticated guidance
mechanism, axon bundles enter the hindlimb and stereotypically
bifurcate into ventral and dorsal nerve trunks. More distally, the
growth cones encounter several additional choice points, in
which selected subsets of nerve fibers continue to branch off and
finally defasciculate at their predetermined target destination.
This last step of innervation is likely regulated by the most com-
plex and hitherto still essentially unknown interplay of multiple
receptors and corresponding guidance cues.
Commonly, the identification of guidance molecules that
function at any stage of limb development has been rather diffi-
cult. Best characterized so far are ligand–receptor systems that
cooperate in dorsoventral pathfinding decisions at the entrance
of the hindlimb. This includes pairs of ephrinA:EphA4 and eph-
rinB:EphB receptors controlling selective axonal growth by re-
pulsion (Helmbacher et al., 2000; Eberhart et al., 2002; Luria et
al., 2008) and the ligand–receptor combination of glial cell line-
derived neurotrophic factor:Ret mediating axon attraction
(Kramer et al., 2006). Mice lacking one or several of these signal-
ing components indeed display different degrees ofmisrouting of
motor axons at the dorsoventral choice point, but the basic out-
line of themain nerve pathways remains unaffected (Helmbacher
et al., 2000; Kramer et al., 2006; Luria et al., 2008). These findings
clearly establish their role as specific cues, yet they indicate that
other molecules operate on a more general level of axonal
guidance.
As a result of their consistent association with barrier tissues,
PNA-binding glycoproteins and chondroitin-6-sulfate-carrying
proteoglycans have generally been considered the prime candi-
dates for such a universal role, namely as inhibitors of neural crest
cell migration and axonal growth in the periphery (Oakley and
Tosney, 1991; Oakley et al., 1994). The best match in the search
for the CSPG component is versican, because its splice variants
V0 and V1 show a highly similar temporospatial distribution in
the developing trunk and hindlimbs (Landolt et al., 1995) and
because it impedes themigration of neural crest stem cells in vitro
(Dutt et al., 2006). We now demonstrate that these two versican
isoforms are also the main carriers of PNA-reactive carbohy-
Figure 6. Inhibitory potential of versican V0/V1 on neurite outgrowth in stripe-choice assays. Neurites from E10 chick dorsal root ganglions grow on laminin-1 stripes but avoid alternating lanes
coated with laminin-1 plus intact or core glycoprotein preparations of versican V1 (B, C and G, H, respectively) or of a V0/V1 mix (D, E and I, J ). For the coating of the test stripes, a 100g/ml
laminin-1 solution was supplemented with variable amounts of versican. The corresponding versican concentrations are indicated above the panels. On the versican-free control lanes, 20g/ml
laminin-1 was applied. The stripe patterns of the control assays (A, F ) were prepared analogously, but versican was omitted in the test stripes; control (F ) included in addition chondroitinase and
enzyme buffer in the test lanes. Neurofilaments (red) and versican (green) have been visualized by double immunofluorescence staining. Ratios (SD) of averaged gray values of the axon-specific
red fluorescence in versican-free versus the adjacent versican-containing lanes are shown below the panels. Scale bar, 100m.
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drates at the corresponding locations and
therewith tie our versican findings to the
knowledge of PNA-binding barrier com-
ponents. This integration may as well en-
compass the only partly characterized
growth cone collapse-inducing 48 and 55
kDa glycoproteins, which have been iso-
lated previously by PNA affinity chroma-
tography from extracts of cultured
somitic strips (Davies et al., 1990). Con-
sidering our current lectin blots with al-
most exclusive staining of the versican
core glycoproteins in embryonic trunk ex-
tracts, it appears unlikely that these for-
mer preparations of PNA-binding protein
contained no versicans. They must have
rather evaded detection as a result of their
large sizes and dispersion in gel electro-
phoresis. It seems therefore likely that at
leastpartsof thegrowth-cone-collapsingac-
tivity ascribed to these smallerPNA-binding
glycoproteins has emanated from “contam-
inating” versicans. Whether the 48 and 55
kDa components represented chondroitin
sulfate-free proteolytic fragments of versi-
can remains presently open.
In a few tissues of the early trunk, such as
the ectoderm and the neural tube, PNA-
binding and versican V0/V1 immunostain-
ingdonot colocalize.Moreover, the initially
expressed versicans, but not the PNA-affinity
sites, disappear from the greater surround-
ing of the notochord afterHH22–HH23. At
this time and location, versican is progres-
sively being substituted by its close relative
aggrecan (Oettinger et al., 1985; Domowicz
et al., 1995). Like versicans, it carries chon-
droitin sulfate side chains and numerous
mucin-type O-glycans, some of which
might maintain the PNA reactivity at this
particular site. However, the early noto-
chordal aggrecan of the trunk region seems
to bind only little PNA according to our
blotting experiments. Aggrecan and versi-
can V0/V1 probably share some inhibitory
functions during the initial stages of PNS
formation. Although aggrecanmay prevent
neural crest cells and neuronal projections
from invading the perinotochordal region
(Perris and Johansson, 1990; Snow et al.,
1990), versicans V0 and V1 seem to be pri-
marily responsible for the nonpermissive
properties of the posterior somite, the early
limb bud, and pelvic girdle. Only later in
development, when versican V0/V1 has long been cleared from the
axonal pathways and when cartilage begins to form, aggrecan and
some other chondroitin sulfate proteoglycans, such as decorin and
type IX collagen, replace versican in the skeletal primordia of the
limb (Shinomura et al., 1984; Lennon et al., 1991; Yamagata et al.,
1993). Of note, defects in versican turnover lead at this advanced
stage to digit malformations (McCulloch et al., 2009).
Despite their intriguing associationwith barrier tissues during
nervous system development, the exploration of the putative
guidance roles of the two largest versican variants has long been
hampered by their extraordinary structural and biochemical
properties. In addition, attempts to approach functional aspects
by gene knock-out experiments inmice or by overexpression and
knockdown in chick embryos have been frustrating as a result of
the early lethality of versican null mice (Mjaatvedt et al., 1998)
and the relative inefficiency of in ovo electroporation of mesen-
chymal cells in the early limbs, respectively (our unpublished
observations). Only the recent elaboration of protocols to isolate
Figure 7. Growth cone collapse and retraction of DRG neurites after contact with versican-containing substrate. Still images
from time-lapse video microscopy (A–F ) documenting the axon growth behavior of E10 chick DRG axons on a laminin-1 (LN)
substrate either containing or lacking versican V0/V1 (VC). The boundary to the area coatedwith laminin plus versican V0/V1 (100
g/ml each) is marked with a stippled line. At 0 and 63 min, the growth cone (arrowhead) is moving forward in direction of the
versican-containing region. Contacting versican after 69 min, it collapses and the axon rapidly retracts back toward the cell body.
After 87 min, the original position is reached (F ). Scale bar: A–F, 25m. Immunofluorescence overlays of substrate stainings of
versican (G, H, J–L) or laminin-1 (I ) and axonin-1-specific neurite-labeling reveal growth cones with partly to fully extended
structures during advancement on a versican-free zone between versican-containing stripes (G, H ) or across the border of two
differentially coated laminin-1 control areas (I; 100 g/ml coating above and 20 g/ml below arrowhead). A fully collapsed
morphology is, however, invariably observed near the ends of versican-free lanes (arrowheads in J,K ). L, A neuronal cell body near
the versican-containing surface projects a long neurite perpendicularly away from versican, whereas a short second process
extends strictly parallel to the border. Scale bar: G–L, 10m.
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larger quantities of intact V0 and V1 isoforms (Dutt et al., 2006)
has enabled us to study the inhibitory potential of versicans in
peripheral axon growth in vitro and in vivo. In every assay of our
present study, versican V0/V1 proved to override the axon
growth promotion of extracellular matrix components such as
laminin-1 and collagen-I. Most of this inhibitory potential ap-
pears to reside in the versican core protein structure, because
complete removal of the chondroitin sulfate chains cannot neu-
tralize this function. Nevertheless, the glycosaminoglycans and
mucin-type O-glycans are certainly required for the structural
integrity, which might explain the partial reduction of the inhib-
itory capacity of versicans after chondroitinase digestion.
The axonal response induced during encounter of versican
V0/V1-containing areas is highly concentration dependent and
ranges in our functional experiments from rapid retraction and
deflection to defasciculation and growth arrest. These latter
forms of attenuated versican inhibition are frequently observed
in the collagen gel assays in vitro and in the injected hindlimbs in
vivo. Compared with their endogenous counterparts, the ectopi-
cally positioned versicans V0/V1 are usually limited in quantity.
Moreover, they are in vivo confronted with emerging proteolytic
processes typically clearing the proteoglycans from future nerve
pathways. By repeating the injections in regular intervals, we
could at least partly circumvent this problem as illustrated by the
clear inhibitory effects of versican observed in our in ovo study.
Interestingly, a similar concentration dependency of versican
seems to control axonal behavior in the developing optic tectum
of the chicken CNS (Yamagata et al., 1995). Here graded levels of
versicans V0/V1 are involved in the pathway restriction of retinal
axons and in the regulation of lamina-specific arborization and
presynaptic maturation.
Whether versicanV0 andV1 act alone or in concert with other
factors in the different boundary tissues is currently not known.
However, concepts of direct functional links between these pro-
teoglycans and semaphorins (Kantor et al., 2004; Huber et al.,
2005) and/or ephrins (Wang and Anderson, 1997) in certain se-
lective axonal barriers seem highly realistic and thus should be
included in future strategies to explore the
guidance processes in the developing ner-
vous system.
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